Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)-Reference-Cited by-同舟云学术

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Published:2015-02-13 Issue:4 Volume:17 Page:395-402
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Bethel M. A.¹,Green J. B.²,Milton J.¹,Tajar A.¹,Engel S. S.³,Califf R. M.⁴,Holman R. R.¹,

Affiliation:

1. Diabetes Trials Unit; Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford; Oxford UK

2. Division of Endocrinology, Department of Medicine; Duke University Medical Center; Durham NC USA

3. Merck Research Laboratories; Merck Sharp & Dohme Corp.; Whitehouse Station NJ USA

4. Duke Translational Medicine Institute; Duke University; Durham NC USA

Funder

Merck Sharp & Dohme Corp.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12441/fullpdf

Reference28 articles.

1. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR);Perk;Eur Heart J,2012

2. Standards of medical care in diabetes-2014;American Diabetes Association;Diabetes Care,2014

3. Why don't physicians follow clinical practice guidelines? A framework for improvement;Cabana;JAMA,1999

4. National study of physician awareness and adherence to cardiovascular disease prevention guidelines;Mosca;Circulation,2005

5. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey;Yusuf;Lancet,2011

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analytical quality by design approach for the development of high‐performance liquid chromatography method for simultaneous analysis of metformin and sitagliptin in the presence of major degradation products;Journal of Separation Science;2024-03

2. Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial;Scandinavian Cardiovascular Journal;2023-02

3. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-10-25

4. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China;Cost Effectiveness and Resource Allocation;2021-08-04

5. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes;JACC: Heart Failure;2021-08